Interpreted with family history
The result is considered alongside cancer types, ages at diagnosis and patterns among relatives.
Healthcare & LaboratoryOASIS Health / Hereditary Cancer Risk Testing
GERMLINE TESTING
Hereditary Cancer
Hereditary Cancer Risk Testing
Using family history and genetic information to plan future care.
A germline genetic test that assesses selected inherited variants associated with hereditary cancer syndromes and supports clinical risk-management discussions.
Germline testingInterpreted with family historySpecialist result consultation
03 / 0501
OVERVIEW
About Hereditary Cancer
Some cancers are associated with genetic variants present from birth. Information from hereditary cancer testing may be relevant not only to the person tested but also to biological relatives.
Pre- and post-test genetic consultation, careful interpretation and consideration of appropriate surveillance are important parts of the testing process.
02
FEATURES
Key features
Supports future risk management
Screening schedules, specialist referral and other follow-up may be considered with the healthcare team.
Information relevant to relatives
Privacy and personal preferences should guide whether and how results are shared with family members.
03
SPECIFICATION
Test specification
- Test category
- Germline genetic testing
- Potential candidates
- People whose personal or family history may suggest a hereditary cancer syndrome
- Specimen
- Blood or another validated specimen, depending on the panel
- Method
- Next-generation sequencing and related methods
- Genes
- Final panel composition is being confirmed
- Turnaround
- Approximately 20–25 business days; specimen and analysis status may affect timing
- Access
- Through participating medical institutions
Specifications and turnaround may vary according to specimen quality, transport, analytical status and the menu offered by the medical institution.
04
DETAILS
Reasons to consider testing
A clinician may consider testing after reviewing personal and family history.
- Cancer diagnosed at a relatively young age
- Multiple relatives with related cancer types
- Multiple primary cancers
- Specific pathological characteristics
Result categories
Testing can identify clearly relevant variants as well as findings whose significance is not currently established.
- Pathogenic or likely pathogenic
- Variant of uncertain significance (VUS)
- No clearly pathogenic variant identified within the tested scope
- Classification may change as scientific knowledge evolves
Follow-up after testing
Long-term care is considered in the context of the result and family history.
- Recommended screening and surveillance
- Referral to an appropriate specialist
- Communication with biological relatives
- Targeted testing for relatives when appropriate
05
PROCESS
Testing process
- 01
Eligibility assessment
Personal and family history are reviewed.
- 02
Genetic consultation
Potential implications, limitations and secondary findings are discussed.
- 03
Consent and sampling
A specimen is collected after informed consent.
- 04
Analysis and classification
Selected genes are analysed and variants are classified.
- 05
Disclosure and follow-up
A clinician explains the result and discusses appropriate management.
06
FAQ
Frequently asked questions
QDoes a pathogenic variant mean that I will definitely develop cancer?＋
ANo. Many variants increase probability but do not make cancer inevitable. Interpretation depends on the gene, age, family history and other factors.
QCan the result affect my relatives?＋
AA germline variant may also be relevant to biological relatives. A genetics professional can help consider whether and how to share this information.
Important information
The final gene list and panel specification are being prepared. Formal specifications, consent documents, report samples and specialist review will be completed before implementation.